Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to $1.0 million.

  • AC Immune's Share-based Compensation fell 2817.89% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 1339.29%. This contributed to the annual value of $6.2 million for FY2024, which is 2688.98% up from last year.
  • Per AC Immune's latest filing, its Share-based Compensation stood at $1.0 million for Q3 2025, which was down 2817.89% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Share-based Compensation registered a high of $2.2 million during Q1 2024, and its lowest value of $574678.4 during Q3 2022.
  • In the last 5 years, AC Immune's Share-based Compensation had a median value of $1.1 million in 2024 and averaged $1.2 million.
  • As far as peak fluctuations go, AC Immune's Share-based Compensation tumbled by 6195.75% in 2022, and later surged by 7080.44% in 2023.
  • AC Immune's Share-based Compensation (Quarter) stood at $1.1 million in 2021, then dropped by 18.57% to $922801.3 in 2022, then decreased by 2.63% to $898501.6 in 2023, then grew by 22.85% to $1.1 million in 2024, then fell by 7.93% to $1.0 million in 2025.
  • Its Share-based Compensation was $1.0 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.7 million in Q1 2025.